Spyglass Topco Agrees to Acquire Surgery Partners for $23.50 per Share

This is a definitive, material acquisition agreement and therefore qualifies as a forward-looking merger-and-acquisition development. The supplied SEC-derived summary identifies Spyglass Topco as the merger counterparty, while the BusinessWire and Bloomberg material refer to HealthSpan Partners or a Bon Secours Mercy Health affiliate; the common target, all-cash structure, $23.50 per-share consideration and approximately $5.7 billion enterprise value indicate these sources describe the same transaction. The agreement was signed and became effective on October 23, 2026, so the occurrence timestamp reflects that date rather than the October 26 publication dates; the exact signing time is not provided. Importance is high because this is a large take-private transaction, while surprise is moderately high because earlier context indicated potential buyer interest but not definitive terms. Surgery Partners is approved as the directly affected issuer, and Tenet, HCA and UnitedHealth are approved as publicly traded ASC operators with a supported competitive channel; Stryker and Henry Schein are excluded because no specific supply contract, volume commitment or other direct commercial impact is disclosed.